# Astellas Pharma Europe Ltd. clinical trials: 31 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 31 trials with Astellas Pharma Europe Ltd. as lead sponsor, 2 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Astellas Pharma Europe Ltd.: 31 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/astellas-pharma-europe-ltd

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 31
- Recruiting or not yet: 2
- Read on: November 19, 2026

## Trials

The 25 newest of 31, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 5, 2026 | NCT07858500 | Zolbetuximab and Other Cancer Treatments in People With Advanced Gastric or GEJ Cancer in Clinical Practice (RADIANCE) | Astellas Pharma Europe Ltd. | Observational | Not yet recruiting | Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable... | 1,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07858500) |
| May 22, 2026 | NCT07602530 | A Study in Canada to Follow Outcomes of Women in Menopause Treated With Fezolinetant for Hot Flashes, When Given in Clinical Practice | Astellas Pharma Europe Ltd. | Observational | Recruiting | Hot Flashes | 238 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07602530) |
| March 6, 2026 | NCT07455812 | A Study in Germany to Learn About the Value of Fezolinetant in Treating Hot Flashes and Night Sweats in Women During Menopause | Astellas Pharma Europe Ltd. | Observational | Completed | Hot Flashes | 105 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07455812) |
| March 29, 2022 | NCT05300568 | A Survey About Trade-offs When Choosing Menopause Treatments | Astellas Pharma Europe Ltd. | Observational | Completed | Moderate to Severe Vasomotor Symptoms | 1,465 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05300568) |
| October 19, 2021 | NCT05083884 | A Survey About Hot Flashes in Women Going Through the Menopause | Astellas Pharma Europe Ltd. | Observational | Completed | Menopause, Vasomotor Symptoms | 2,176 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05083884) |
| August 23, 2021 | NCT05015998 | A Study to Evaluate the ePidemiology of anEmia Associated With chroNic Kidney Disease in Patients in Primary Care Using The Stockholm... | Astellas Pharma Europe Ltd. | Observational | Completed | Chronic Kidney Disease | 45,637 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05015998) |
| August 1, 2019 | NCT04042350 | Retrospective Analysis Assessing Clinical Risk Factors for Cardiovascular Events and Mortality and Development of a Risk Calculator in... | Astellas Pharma Europe Ltd. | Observational | Completed | Chronic Kidney Disease (CKD) | 2,773 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04042350) |
| August 8, 2018 | NCT03619980 | A Non-Interventional Study to Evaluate Time to Event and Healthcare Resource Utilisation for Prostate Cancer Participants Throughout the... | Astellas Pharma Europe Ltd. | Observational | Completed | Prostate Cancer | 6,908 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03619980) |
| March 15, 2018 | NCT03465969 | A Study to Compare the Finger Prick Whole Blood MITRA Assay Method With the Established Venepuncture Whole Blood Method for Quantitative... | Astellas Pharma Europe Ltd. | Phase 4 | Completed | Kidney Transplantation, Liver Transplantation | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03465969) |
| August 2, 2016 | NCT02852876 | Study to Evaluate the Safety and Pharmacokinetics of Single Doses of ASP2151 in Healthy Male Subjects and the Effects of Food | Astellas Pharma Europe Ltd. | Phase 1 | Completed | Herpes Genitalis, Herpes Zoster | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02852876) |
| September 22, 2015 | NCT02555787 | Global, Multicentre, Non Interventional Advagraf Conversion Registry in Kidney Transplant Patients | Astellas Pharma Europe Ltd. | Observational | Completed | Kidney Transplantation | 4,430 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02555787) |
| July 13, 2015 | NCT02495974 | European Observational Study of Enzalutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC) | Astellas Pharma Europe Ltd. | Observational | Completed | Metastatic Castration Resistant Prostate Cancer | 1,763 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02495974) |
| May 7, 2015 | NCT02437591 | Study to Evaluate the Pharmacokinetics of Fidaxomicin in Inflammatory Bowel Disease (IBD) Subjects With Clostridium Difficile Infection... | Astellas Pharma Europe Ltd. | Phase 4 | Completed | Inflammatory Bowel Disease (IBD), Clostridium Difficile Infection (CDI) | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02437591) |
| March 3, 2015 | NCT02377609 | To Validate an Analytical Method to Measure Concentration of Tacrolimus in Blood Taken From Finger Pricks | Astellas Pharma Europe Ltd. | Observational | Terminated | Validation, Dried Blood Spot, Transplant Patients | 108 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02377609) |
| December 19, 2014 | NCT02320773 | A Prospective Non-interventional Study in Overactive Bladder (OAB) Patients Prescribed Betmiga® as Part of Routine Clinical Practice | Astellas Pharma Europe Ltd. | Observational | Completed | Urgency Incontinence, Urinary Bladder Overactive, Overactive Bladder, Urologic Diseases, Urinary Bladder Diseases | 863 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02320773) |
| November 11, 2014 | NCT02288247 | A Study to Assess the Benefit of Treatment Beyond Progression With Enzalutamide in Men Who Are Starting Treatment With Docetaxel After... | Astellas Pharma Europe Ltd. | Phase 3 | Completed | Metastatic Castration Resistant Prostate Cancer | 688 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02288247) |
| October 2, 2014 | NCT02254967 | A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of... | Astellas Pharma Europe Ltd. | Phase 4 | Completed | Clostridium Difficile | 364 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02254967) |
| April 21, 2014 | NCT02118896 | Study to Ascertain if Prolonged Release Tacrolimus (FK506E - MR4) is Safe and Effective When Used in the Long Term and in Combination With... | Astellas Pharma Europe Ltd. | Phase 3 | Completed | Heart Transplantation, Liver Transplantation, Kidney Transplantation | 850 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02118896) |
| February 7, 2014 | NCT02057484 | A 5 Year Follow-up of Patients Who Were Previously Enrolled Into an Advagraf Trial Following a Liver or Kidney Transplant | Astellas Pharma Europe Ltd. | Observational | Completed | Liver Transplant, Kidney Transplant | 2,300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02057484) |
| August 30, 2013 | NCT01933022 | A Study in Patients With Metastatic Prostate Cancer to Assess How the Drug Eligard®, Affects Certain Markers in Blood and Urine, Which Are... | Astellas Pharma Europe Ltd. | Phase 4 | Terminated | Metastatic Prostate Cancer | 1 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01933022) |
| July 26, 2013 | NCT01908829 | A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin) | Astellas Pharma Europe Ltd. | Phase 3 | Completed | Urinary Bladder Diseases, Urinary Bladder Overactive, Urologic Diseases | 2,174 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01908829) |
| January 25, 2013 | NCT01775397 | A Post-marketing, Blinded Study to Investigate How Effective Fidaxomicin is Compared to Vancomycin in the Sustained Cure of Clostridium... | Astellas Pharma Europe Ltd. | Phase 4 | Terminated | Clostridium Difficile | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01775397) |
| November 29, 2012 | NCT01737294 | Observation of the Use of QUTENZA™ in Standard Clinical Practice | Astellas Pharma Europe Ltd. | Observational | Completed | Peripheral Neuropathic Pain | 429 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01737294) |
| October 24, 2012 | NCT01713426 | A Study to Compare QUTENZA With Pregabalin for the Treatment of Peripheral Neuropathic Pain (PNP) After 8 Weeks of Treatment | Astellas Pharma Europe Ltd. | Phase 4 | Completed | Non-diabetic Painful Peripheral Polyneuropathy, Postherpetic Neuralgia (PHN), Peripheral Nerve Injury (PNI) | 568 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01713426) |
| July 13, 2012 | NCT01639794 | Vesitirim™ in Men Postmarketing Observational Study | Astellas Pharma Europe Ltd. | Observational | Completed | Lower Urinary Tract Symptoms (LUTS), Overactive Bladder (OAB) | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01639794) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 2 |
| Phase 2 | 2 |
| Phase 3 | 4 |
| Phase 4 | 8 |
| Observational | 15 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 24 |
| Terminated | 5 |
| Recruiting | 1 |
| Not yet recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Urinary Bladder, Overactive | 5 |
| Prostatic Neoplasms | 4 |
| Urologic Diseases | 3 |
| Urinary Bladder Diseases | 3 |
| Urinary Incontinence | 2 |
| Hot Flashes | 2 |
| Renal Insufficiency, Chronic | 2 |
| Inflammatory Bowel Diseases | 1 |
| Clostridium Infections | 1 |
| Infections | 1 |
| Lower Urinary Tract Symptoms | 1 |
| Neuralgia, Postherpetic | 1 |
| Peripheral Nerve Injuries | 1 |
| Herpes Genitalis | 1 |
| Herpes Zoster | 1 |
| Adenocarcinoma | 1 |
| Neoplasms | 1 |
| Stomach Neoplasms | 1 |
| Neoplasm Metastasis | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Appellate practice law firms in the United States](https://specstream.ai/data/businesses/appellate-practice-law-firms/united-states)
- [French restaurants in the United States](https://specstream.ai/data/businesses/french-restaurants/united-states)
- [Real estate firms in the United States](https://specstream.ai/data/businesses/real-estate-firms/united-states)
- [Brewing supply stores in the United States](https://specstream.ai/data/businesses/brewing-supply-stores/united-states)
- [Iron fabricators in the United States](https://specstream.ai/data/businesses/iron-fabricators/united-states)
- [Temp agencies in the United States](https://specstream.ai/data/businesses/temp-agencies/united-states)
